1. Home
  2. NVNI vs ACET Comparison

NVNI vs ACET Comparison

Compare NVNI & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nvni Group Limited

NVNI

Nvni Group Limited

HOLD

Current Price

$1.32

Market Cap

12.9M

Sector

N/A

ML Signal

HOLD

Logo Adicet Bio Inc.

ACET

Adicet Bio Inc.

HOLD

Current Price

$7.23

Market Cap

69.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NVNI
ACET
Founded
2019
1947
Country
Brazil
United States
Employees
618
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
12.9M
69.6M
IPO Year
N/A
2017

Fundamental Metrics

Financial Performance
Metric
NVNI
ACET
Price
$1.32
$7.23
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$56.00
AVG Volume (30 Days)
79.8K
117.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$6.67
N/A
Revenue Next Year
$26.67
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.14
$0.45
52 Week High
$4.94
$9.05

Technical Indicators

Market Signals
Indicator
NVNI
ACET
Relative Strength Index (RSI) 42.93 50.17
Support Level $1.10 $6.54
Resistance Level $1.64 $8.46
Average True Range (ATR) 0.12 0.46
MACD 0.04 -0.05
Stochastic Oscillator 63.78 37.24

Price Performance

Historical Comparison
NVNI
ACET

About NVNI Nvni Group Limited

Nvni Group Ltd is a holding company that conducts all of its business through Nuvini SA and Nuvini acquired companies. Nuvini S.A. acquires and operates software companies within SaaS markets in Brazil. Nuvini S.A. is the private serial software business acquirer in Brazil and intends to use funding and capital markets access to continue expanding its acquisition plans in Brazil and Latin America. The Company has determined that it has a single operating and reportable segment which is multi-vertical SaaS solution model.

About ACET Adicet Bio Inc.

Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.

Share on Social Networks: